NCT00414856

Effects of AFQ056 and Baclofen on Meal-Induced Gastroesophageal Reflux

A Multi-Center, Randomized, Double-Blind, Placebo- and Positive-Control, Double-Dummy, 3 Parallel Cohort, Two-Way Crossover Single Oral Dose Study in GERD (Gastro Esophageal Reflux Disease) Patients to Evaluate the Effects of AFQ056 and Baclofen (Positive Control) on the Incidence of Meal-Induced Gastro Esophageal Reflux Events

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (estimated)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study will assess the safety and tolerability of oral single dose applications of AFQ056 in GERD patients.

Conditions

• Gastroesophageal Reflux Disease

Interventions

Type	Name	Description
DRUG	AFQ056

Timeline

• Start date: 2006-08-01
• First posted: 2006-12-22
• Last updated: 2007-06-22

Locations

4 sites across 4 countries: Belgium, France, Germany, Switzerland